Select Page
Event info
Date:08 Jun
Time:10:00 - 11:00

MVA Inspirational Webinar Series – Biomarker Assays

Implementing and Validating Meso Scale Discovery – ECL Detection for Clinical Trials

When implementing biomarker strategies for clinical trials, it is not only important to choose the right analysis platform but also have the assays validated and performed to meet regulatory submission requirements.

Unilabs Serving Pharma group, in collaboration with Meso-Scale Discovery (MSD) will present the capabilities and opportunities for the use of the MSD-ECL platform for biomarker analysis in clinicals trials.

Unilabs experienced scientific team will share their experience and offer guidance on how to set-up and validate the MSD platform, and which important aspects to consider.


Date: 8th June 2021
Time: 10:00 – 11:00
Venue: Online





9:50 Online platform opens for registering participants
10:00 Welcome and introduction of speakers
David Munis Zepernick, Head of Business Development and Public Affairs, Medicon Valley Alliance
10:05 Advances in Multiplex ECL Detection of Protein Biomarkers
Anders Elleby, Meso-Scale Diagnostics
10:30 Practical Considerations for Biomarker Validation in Clinical Trials
Colin Farrell, Ph.D. Unilabs
10:50 Q&A
11:00 End of webinar



Colin Farrell, Ph.D, Head of Immunoassays at Unilabs YBS, has over 30 years experience in the development of immunoassays. Dr. Farrell’s career has taken him through roles in small biotech, big pharma and large CRO’s, including Covance and Astra Zeneca, developing bioanalytical methods and immunoassays for drug discovery programs. Using the MSD platform, he routinely develops pK assays and ADA methods for clinical studies. These studies have included biomarker analysis for diverse indications such as immuno-oncology, neurodegenerative and infectious disease areas.
Anders Elleby, MSc. Since leaving university, Anders Elleby has had a number of sales and application focused roles in the Nordics. His focus has been on flow/FACS based applications as well as multiplex biomarker detection and since 2016 Anders has managed Denmark for Meso Scale Diagnostics. Through his interactions with researchers in academia, biotech and pharma, Anders has gathered an extensive experience allowing him to guide researchers to fit-for-purpose biomarker solutions.


Organized in collaboration with